Welcome to our dedicated page for Senti Bioscience news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Bioscience stock.
Senti Biosciences, Inc. (Senti Bio) (NASDAQ: SNTI) is a clinical-stage biotechnology company developing cell and gene therapies that incorporate engineered Gene Circuits. This news page aggregates company announcements, scientific updates, and corporate disclosures so readers can follow how Senti Bio advances its Gene Circuit platform and clinical programs over time.
A major focus of Senti Bio’s news flow is SENTI-202, its first-in-class Logic Gated off-the-shelf CAR-NK cell therapy product candidate. Company releases describe ongoing Phase 1 clinical evaluation of SENTI-202 in adults with relapsed or refractory CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndrome. Updates have highlighted clinical and pharmacodynamic data, presentations at the American Society of Hematology (ASH) Annual Meeting, and FDA designations such as Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation.
Visitors can also expect news on Senti Bio’s participation in investor and scientific conferences, quarterly financial result announcements, and communications about its broader Gene Circuit platform. These items provide context on how the company positions its synthetic biology approach, preclinical work in NK and T cells, and efforts to explore Gene Circuits in other modalities and disease areas through partnerships.
For investors and observers tracking SNTI, this page offers a centralized view of press releases and related information, from clinical data readouts and regulatory milestones to corporate presentations. Checking this feed periodically can help users understand the evolution of Senti Bio’s pipeline and its activities within the cell and gene therapy landscape.
Senti Biosciences (Nasdaq: SNTI) announced that CEO and co-founder Timothy Lu, M.D., Ph.D. will present at the Leerink Partners 2026 Global Healthcare Conference in Miami on March 9, 2026 at 2:20 PM ET. A live webcast will be available and a replay will be posted on the company’s Investors Events page.
This is a corporate presentation by a clinical-stage company developing cell and gene therapies using its Gene Circuit platform.
Senti Biosciences (Nasdaq: SNTI) announced that CEO Timothy Lu will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, 3:10–3:40 PM ET. The presentation will cover the Gene Circuit platform, pipeline progress, and partnership opportunities. Live audio and video webcasts will be available on the company website.
Senti Bio (Nasdaq: SNTI) participated in the Cell & Gene Live virtual event on February 19, 2026, presenting its Gene Circuit platform and Logic-Gated SENTI-202 approach.
According to the company, the presentation discussed how Gene Circuit design aims to enhance precision, control, and functionality in engineered cell therapies; a recording is available on demand.
Senti Biosciences (Nasdaq: SNTI) completed enrollment in its Phase 1 trial of SENTI-202, a first-in-class CD33/FLT3 Logic Gated CAR NK therapy for relapsed or refractory acute myeloid leukemia (R/R AML).
Positive ASH 2025 data reported deep, MRD-negative, durable complete remissions and a favorable safety profile. SENTI-202 holds RMAT designation; the company plans FDA discussions in H1 2026 and is designing a potential pivotal registration program and exploring expansion to newly diagnosed and pediatric AML. ClinicalTrials.gov identifier: NCT06325748.
Senti Biosciences (Nasdaq: SNTI) will present on-stage at Healthcare Conference Taipei 2026 on Feb 10, 2026. The eight-minute session (10:30–10:40 AM local, Regent Ballroom, Track 1) will cover the Gene Circuit platform, pipeline progress, strategic priorities and partnership opportunities.
Management will host post-presentation networking at Table #1 in the Level 3 foyer.
Senti Biosciences (Nasdaq: SNTI) participated in a Virtual Investor CEO Connect segment on Jan 14, 2026, where CEO Timothy Lu discussed two regulatory milestones and new clinical data. The U.S. FDA granted RMAT designation to SENTI-202, a potential first-in-class logic gated off-the-shelf CAR-NK investigational therapy for relapsed/refractory hematologic malignancies including AML, building on an Orphan Drug designation awarded in June. Dr. Lu also reviewed data from 20 patients (18 with evaluable responses) in the ongoing multinational SENTI-202 trial, with results presented at the American Society of Hematology (ASH) Annual Meeting.
Senti Biosciences (Nasdaq: SNTI) announced that Dr. Timothy Lu, co-founder and CEO, will serve as a panelist at Biotech Showcase 2026 in San Francisco, taking place January 12–14, 2026. The panel, titled "Engineering the Future: Advances in Cell and Gene Therapies", is scheduled for Tuesday, January 13, 2026 at 8:00 AM PST in Workshop 1 (Yosemite A).
The session features industry leaders from pharmaphorum, Diakonos Oncology, Opus Genetics, IN8bio, and Epicrispr Biotechnologies and will discuss advances in cell and gene therapies using technologies such as gene circuits. Investors can view session details on the conference website.
Senti Biosciences (Nasdaq: SNTI) announced that on Dec 12, 2025 its board granted inducement stock options to one new employee to purchase 13,680 shares at an exercise price of $1.31 per share. The awards were granted under the company's Amended and Restated 2022 Inducement Equity Plan and were described as material inducements under Nasdaq Listing Rule 5635(c)(4). The Plan was initially adopted by the board on Aug 5, 2022. No additional financial guidance, vesting schedule, or dilutive impact was disclosed in the announcement.
Senti Bio (Nasdaq: SNTI) announced the FDA has granted RMAT designation to SENTI-202 on December 9, 2025 for adults with relapsed or refractory acute myeloid leukemia (R/R AML).
Designation follows an Orphan Drug designation in June 2025 and is supported by Phase 1 data presented at ASH on December 8, 2025 showing 50% ORR, 42% CR/CRh at the RP2D and a 7.6-month median duration of composite complete remission; data also show selective killing of leukemic cells while sparing healthy progenitors.
Senti Biosciences (Nasdaq: SNTI) reported updated SENTI-202 Phase 1 data in 20 relapsed/refractory AML patients (18 evaluable) presented at ASH 2025 on Dec 9, 2025. Key results at the RP2D: 50% ORR, 42% CR/CRh; overall: 50% ORR, 39% CR/CRh. 100% of CRs and ~80% of responses were MRD negative. Median duration of composite complete remissions across all patients was 7.6 months (KM estimate). SENTI-202 showed pharmacodynamic validation of its OR/NOT Logic Gate targeting, a favorable safety profile with no DLTs or SENTI-202-related SAEs, and received FDA RMAT designation.